BACKGROUND: Secondary erythrocytosis results in increased shear stress in cyanotic congenital heart disease (CCHD), which may modify the balance between vasodilators and vasoconstrictors and affect systemic endothelial function. Because no data are available on systemic vasomotion, systemic endothelial function and nitric oxide (NO) availability were investigated in CCHD patients. METHODS AND RESULTS: Responses to arterial endothelium-dependent (acetylcholine [Ach]) and -independent (sodium nitroprusside [SNP]) vasodilation, NO synthase blockade (NG-monomethyl-L-arginine [L-NMMA]), endothelin-1 (ET-1), and ET-1 receptor blockade by BQ-123 in 11 CCHD patients (O2 saturation <90%; mean+/-SD, 79+/-1%; mean+/-SD age, 39+/-2 years) were compared with those in 10 age-matched healthy referents by using forearm venous occlusion plethysmography. Resting forearm blood flow (FBF) was lower in CCHD patients than in referents (2.4+/-0.2 versus 3.5+/-0.4 mL.min(-1).100 mL(-1) of forearm volume [FAV], P<0.05). Although the response to SNP was similar in both groups (CCHD, 2.0+/-0.3 to 8.3+/-1.0; referents, 3.6+/-0.7 to 11.9+/-1.2 mL.min(-1).100 mL(-1) of FAV; P>0.1), the response to Ach was markedly reduced in CCHD (maximal increase in FBF, 2.8+/-0.8 versus 37.5+/-4.4 mL.min(-1).100 mL(-1) of FAV; P<0.0001). l-NMMA was less effective in CCHD (decrease in FBF, 25+/-6% versus 40+/-4%; P<0.05). ET-1 caused less vasoconstriction in the CCHD group (-25+/-9% versus -51+/-7%, P<0.05), but the response to BQ-123 was similar in both groups (32+/-9% versus 27+/-9%). CONCLUSIONS: Systemic endothelial dysfunction is evident in CCHD patients as shown by strikingly reduced endothelial vasodilation to Ach. The response to exogenous ET-1 is reduced, possibly because of elevated endogenous ET-1 levels, but the effects of endogenous ET-1 on arterial tone are not enhanced, as indicated by the similar response to ET-1 blockade.
BACKGROUND: Secondary erythrocytosis results in increased shear stress in cyanotic congenital heart disease (CCHD), which may modify the balance between vasodilators and vasoconstrictors and affect systemic endothelial function. Because no data are available on systemic vasomotion, systemic endothelial function and nitric oxide (NO) availability were investigated in CCHDpatients. METHODS AND RESULTS: Responses to arterial endothelium-dependent (acetylcholine [Ach]) and -independent (sodium nitroprusside [SNP]) vasodilation, NO synthase blockade (NG-monomethyl-L-arginine [L-NMMA]), endothelin-1 (ET-1), and ET-1 receptor blockade by BQ-123 in 11 CCHDpatients (O2 saturation <90%; mean+/-SD, 79+/-1%; mean+/-SD age, 39+/-2 years) were compared with those in 10 age-matched healthy referents by using forearm venous occlusion plethysmography. Resting forearm blood flow (FBF) was lower in CCHDpatients than in referents (2.4+/-0.2 versus 3.5+/-0.4 mL.min(-1).100 mL(-1) of forearm volume [FAV], P<0.05). Although the response to SNP was similar in both groups (CCHD, 2.0+/-0.3 to 8.3+/-1.0; referents, 3.6+/-0.7 to 11.9+/-1.2 mL.min(-1).100 mL(-1) of FAV; P>0.1), the response to Ach was markedly reduced in CCHD (maximal increase in FBF, 2.8+/-0.8 versus 37.5+/-4.4 mL.min(-1).100 mL(-1) of FAV; P<0.0001). l-NMMA was less effective in CCHD (decrease in FBF, 25+/-6% versus 40+/-4%; P<0.05). ET-1 caused less vasoconstriction in the CCHD group (-25+/-9% versus -51+/-7%, P<0.05), but the response to BQ-123 was similar in both groups (32+/-9% versus 27+/-9%). CONCLUSIONS: Systemic endothelial dysfunction is evident in CCHDpatients as shown by strikingly reduced endothelial vasodilation to Ach. The response to exogenous ET-1 is reduced, possibly because of elevated endogenous ET-1 levels, but the effects of endogenous ET-1 on arterial tone are not enhanced, as indicated by the similar response to ET-1 blockade.
Authors: Christian M Pedersen; Michael R Schmidt; Bente Mortensen; Hussain Contractor; Hans Erik Bøtker; Rajesh K Kharbanda; Keld E Sørensen Journal: Pediatr Cardiol Date: 2009-07-30 Impact factor: 1.655
Authors: Heather Y Sun; Katie Jo Stauffer; Susan E Nourse; Chau Vu; Elif Seda Selamet Tierney Journal: Pediatr Cardiol Date: 2017-03-27 Impact factor: 1.655
Authors: Alexander R Opotowsky; Lilamarie E Moko; Jonathan Ginns; Marlon Rosenbaum; Matthias Greutmann; Jamil Aboulhosn; Abbie Hageman; Yuli Kim; Lisa X Deng; Jasmine Grewal; Ali N Zaidi; Ghadeera Almansoori; Erwin Oechslin; Michael Earing; Michael J Landzberg; Michael N Singh; Fred Wu; Anand Vaidya Journal: J Clin Endocrinol Metab Date: 2015-01-12 Impact factor: 5.958
Authors: Julie Bjerre Tarp; Peter Clausen; David Celermajer; Christina Christoffersen; Annette Schophuus Jensen; Keld Sørensen; Henrik Sillesen; Mette-Elise Estensen; Edit Nagy; Niels-Henrik Holstein-Rathlou; Thomas Engstrøm; Bo Feldt-Rasmussen; Lars Søndergaard Journal: Int J Cardiol Heart Vasc Date: 2020-09-15
Authors: Oktay Tutarel; Agnieszka Denecke; Stefanie M Bode-Böger; Jens Martens-Lobenhoffer; Svjetlana Lovric; Johann Bauersachs; Bernhard Schieffer; Mechthild Westhoff-Bleck; Jan T Kielstein Journal: PLoS One Date: 2012-03-21 Impact factor: 3.240
Authors: Erwin Oechslin; Siegrun Mebus; Ingram Schulze-Neick; Koichiro Niwa; Pedro T Trindade; Andreas Eicken; Alfred Hager; Irene Lang; John Hess; Harald Kaemmerer Journal: Curr Cardiol Rev Date: 2010-11
Authors: Rachael Cordina; Stuart Grieve; Michael Barnett; Jim Lagopoulos; Nathan Malitz; David S Celermajer Journal: Neuroimage Clin Date: 2014-01-04 Impact factor: 4.881